CSIMarket
 


Precision Biosciences Inc  (DTIL)
Other Ticker:  
 
 

DTIL's Revenue Growth by Quarter and Year

Precision Biosciences Inc's Revenue results by quarter and year




DTIL Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 10.60 6.34 8.85
III Quarter September 13.12 7.36 24.04 7.36
II Quarter June 19.79 3.82 68.81 1.08
I Quarter March 8.78 3.32 16.35 7.00
FY   41.69 25.10 115.54 24.29



DTIL Revenue third quarter 2023 Y/Y Growth Comment
Precision Biosciences Inc reported Revenue surge of 78.26% year on year in the third quarter 2023, to $ 13.12 millions, this is lower than Precision Biosciences Inc's recent average Revenue surge of 507.03%.

Looking into third quarter 2023 results within Biotechnology & Pharmaceuticals industry 10 other companies have achieved higher Revenue growth. While Precision Biosciences Inc' s Revenue jump of 78.26% ranks overall at the positon no. 248 in the third quarter 2023.




DTIL Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - 67.19 % -28.36 % -
III Quarter September 78.26 % -69.38 % 226.63 % 51.13 %
II Quarter June 418.06 % -94.45 % 6271.3 % -79.96 %
I Quarter March 164.46 % -79.69 % 133.57 % 28.21 %
FY   - -78.28 % 375.67 % 344.06 %

Financial Statements
Precision Biosciences Inc's third quarter 2023 Revenue $ 13.12 millions DTIL's Income Statement
Precision Biosciences Inc's third quarter 2022 Revenue $ 7.36 millions Quarterly DTIL's Income Statement
New: More DTIL's historic Revenue Growth >>


DTIL Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 44.02 % -73.63 % 20.24 %
III Quarter September -33.7 % 92.67 % -65.06 % 581.48 %
II Quarter June 125.4 % 15.06 % 320.86 % -84.57 %
I Quarter March -17.17 % -47.63 % 84.75 % -
FY (Year on Year)   - -78.28 % 375.67 % 344.06 %




Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #11
Healthcare Sector #94
Overall #248

Revenue Y/Y Growth Statistics
High Average Low
6282.65 % 507.03 % -94.45 %
(Jun 30 2021)   (Jun 30 2022)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #11
Healthcare Sector #94
Overall #248
Revenue Y/Y Growth Statistics
High Average Low
6282.65 % 507.03 % -94.45 %
(Jun 30 2021)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Precision Biosciences Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
583.02 % 59.57 % -84.6 %
(Sep 30 2020)  


DTIL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Precision Biosciences Inc reported fall in Revenue from the second quarter by -33.7% to $ 13.12 millions, from $ 19.79 millions released in the previous reporting period.

Even seasonal circumstance have not recover the III. Quarter for the Precision Biosciences Inc, Haley Morgan, Biotechnology & Pharmaceuticals industry expert allocated in Houston said, she identified further challenges ahead for Precision Biosciences Inc and mentioned that average sequential Revenue growth is at 59.57% for Precision Biosciences Inc.

Within Biotechnology & Pharmaceuticals industry 28 other companies have achieved higher Revenue quarter on quarter growth. While Precision Biosciences Inc's Revenue growth quarter on quarter, overall rank is 1905.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #29
Healthcare Sector #249
Overall #1905
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #29
Healthcare Sector #249
Overall #1905
Revenue Q/Q Growth Statistics
High Average Low
583.02 % 59.57 % -84.6 %
(Sep 30 2020)  


DTIL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Precision Biosciences Inc reported fall in Revenue from the second quarter by -33.7% to $ 13.12 millions, from $ 19.79 millions achived a quarter before.

Even seasonal influence were not able to recover the III. Quarter for the Precision Biosciences Inc, Haley Morgan, Biotechnology & Pharmaceuticals industry expert allocated in Houston pointed out, she voiced some caution towards DTIL's direction and mentioned that average sequential Revenue growth is at 59.57% for Precision Biosciences Inc.

Within Biotechnology & Pharmaceuticals industry 28 other companies have achieved higher Revenue quarter on quarter growth. While Precision Biosciences Inc's Revenue growth quarter on quarter, overall rank is 1905.


Precision Biosciences Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 52.29 $ 46.53 $ 30.56 $ 25.10 $ 20.84
Y / Y Revenue Growth (TTM) 150.91 % 24.04 % -70.18 % -78.28 % -82.35 %
Year on Year Revenue Growth Overall Ranking # 3595 # 3688 # 120 # 8 # 2865
Seqeuential Revenue Change (TTM) 12.37 % 52.25 % 21.77 % 20.44 % -44.45 %
Seq. Revenue Growth (TTM) Overall Ranking # 3444 # 3688 # 2411 # 923 # 3272




Cumulative Revenue growth Comment
Although Precision Biosciences Inc's Annual Revenue growth year on year were below company's average 586.31% , Revenue announced in the Sep 30 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 150.91% year on year, from 24.04% in Jun 30 2023.

In the Healthcare sector 539 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3595, from total ranking in previous quarter at 3688.

Revenue TTM Q/Q Growth Statistics
High Average Low
3672.35 %
586.31 %
-82.35 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 53
Healthcare Sector # 540
Overall # 3595

Revenue TTM Y/Y Growth Statistics
High Average Low
3672.35 %
586.31 %
-82.35 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 53
Sector # 489
S&P 500 # 3444
Cumulative Revenue growth Comment
Although Precision Biosciences Inc's Annual Revenue growth year on year were below company's average 586.31% , Revenue announced in the Sep 30 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 150.91% year on year, from 24.04% in Jun 30 2023.

In the Healthcare sector 539 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3595, from total ranking in previous quarter at 3688.

Revenue TTM Q/Q Growth Statistics
High Average Low
3672.35 %
586.31 %
-82.35 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 53
Healthcare Sector # 540
Overall # 3595

Revenue TTM Y/Y Growth Statistics
High Average Low
3672.35 %
586.31 %
-82.35 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 53
Sector # 489
S&P 500 # 3444




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DTIL's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for DTIL's Competitors
Revenue Growth for Precision Biosciences Inc's Suppliers
Revenue Growth for DTIL's Customers

You may also want to know
DTIL's Annual Growth Rates DTIL's Profitability Ratios DTIL's Asset Turnover Ratio DTIL's Dividend Growth
DTIL's Roe DTIL's Valuation Ratios DTIL's Financial Strength Ratios DTIL's Dividend Payout Ratio
DTIL's Roa DTIL's Inventory Turnover Ratio DTIL's Growth Rates DTIL's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Electrocore Inc 128.14%$ 128.138 millions
Intelgenx Technologies Corp 123.94%$ 123.944 millions
Cardiff Oncology inc 119.42%$ 119.419 millions
Aim Immunotech Inc 119.05%$ 119.048 millions
Xencor Inc116.73%$ 116.726 millions
Journey Medical Corporation114.31%$ 114.315 millions
Surmodics Inc113.94%$ 113.941 millions
Agios Pharmaceuticals Inc 110.44%$ 110.438 millions
Fortress Biotech Inc 110.26%$ 110.261 millions
Reflect Scientific Inc 107.66%$ 107.664 millions
Agile Therapeutics Inc106.03%$ 106.029 millions
Precipio inc 103.97%$ 103.973 millions
Beigene ltd 101.56%$ 101.561 millions
Eton Pharmaceuticals Inc 98.91%$ 98.913 millions
Northwest Biotherapeutics inc97.09%$ 97.087 millions
Revance Therapeutics Inc 95.68%$ 95.678 millions
Evoke Pharma Inc 87.82%$ 87.821 millions
Xoma Corporation84.04%$ 84.035 millions
Catalyst Pharmaceuticals Inc 79.39%$ 79.386 millions
Esperion Therapeutics inc 78.97%$ 78.973 millions
Docgo Inc 78.83%$ 78.828 millions
Precision Biosciences Inc78.19%$ 78.188 millions
Marpai Inc 76.77%$ 76.771 millions
Bicycle Therapeutics Plc76.05%$ 76.053 millions
Intra cellular Therapies Inc 75.56%$ 75.557 millions
Agilon Health Inc 74.95%$ 74.951 millions
Rxsight Inc 72.26%$ 72.263 millions
Elite Pharmaceuticals Inc 71.86%$ 71.860 millions
Procept Biorobotics Corporation71.38%$ 71.379 millions
Pacific Biosciences Of California Inc 69.92%$ 69.917 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com